nimotuzumab + paclitaxel liposome + carboplatin

This combination therapy regimen is being evaluated for the treatment of advanced non-small cell lung cancer (NSCLC). It consists of nimotuzumab, a humanized IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), combined with a chemotherapy backbone of paclitaxel liposome and carboplatin. Nimotuzumab inhibits EGFR-mediated signaling pathways involved in cell proliferation and survival. The paclitaxel liposome component (Lipusu) is a nanoparticle formulation designed to improve the delivery of paclitaxel and reduce systemic toxicity compared to conventional formulations, while carboplatin acts as a DNA-alkylating agent to induce apoptosis. This specific combination, often referred to as the TP or LP regimen in clinical trials led by Tianjin Medical University Cancer Institute and Hospital, aims to enhance therapeutic efficacy through the synergistic effects of targeted biologic therapy and cytotoxic chemotherapy.

Brand names

LipusuTaixinsheng

Other names

Nimotuzumab and TP regimenNimotuzumab + Paclitaxel Liposome + CarboplatinTP-Tianjin Medical University Cancer Institute and Hospital-non-small cell lung cancer